Nanoco Group PLC
www.nanocotechnologies.com
Latest From Nanoco Group PLC
Mark Carnegie-Brown Glides in as CEO
Dr Mark Carnegie-Brown
STOCKWATCH: The strategic review – a prelude to value destruction
The news that a company is conducting a strategic review has grandiose implications of high-flying investment bankers, consultants and board members scouring the world and the management literature for examples of how successful companies have moved from strength to strength, and then how those lesions can be applied to the company in question.
Stockwatch: Can bankers break biotech?
The recent outpouring of soul searching, introspection and discussion prompted by the parting editorial from Greg Smith, a now ex-Goldman Sachs investment banker, has had little linkage to the biotechnology sector. [Smith proposed in his resignation letter that career progression at Goldman Sachs is now contingent not on making money for its investor clients but on making money for Goldman Sachs.]
European Financing: The Money's Back, But How Do You Get It?
Company Information
- Industry
- Biotechnology
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Evolutec Ltd.
- Evolutec Group PLC
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Nanoco Group PLC
- Senior Management
-
David Bloxham, PhD, CEO
John Burke, Chmn. - Contact Info
-
Nanoco Group PLC
Phone: (44) 161 603 79
46 Grafton St.
, M13 9NT
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice